BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $147,028,122 | -43.3% | 2,159,955 | -32.0% | 0.05% | -40.7% |
Q2 2023 | $259,177,350 | +14.8% | 3,175,026 | +4.3% | 0.08% | +9.5% |
Q1 2023 | $225,761,621 | +10.0% | 3,043,020 | +22.9% | 0.07% | +5.7% |
Q4 2022 | $205,238,000 | +16.8% | 2,476,339 | +300.4% | 0.07% | +7.7% |
Q3 2022 | $175,648,000 | -18.4% | 618,425 | -0.4% | 0.06% | -13.3% |
Q2 2022 | $215,231,000 | -20.6% | 620,904 | -0.8% | 0.08% | -6.2% |
Q1 2022 | $271,151,000 | +1.6% | 626,206 | +21.3% | 0.08% | +8.1% |
Q4 2021 | $266,927,000 | +13.6% | 516,057 | +6.4% | 0.07% | -1.3% |
Q3 2021 | $234,988,000 | -21.7% | 484,925 | -27.3% | 0.08% | -19.4% |
Q2 2021 | $300,300,000 | +24.1% | 666,954 | +5.3% | 0.09% | +16.2% |
Q1 2021 | $242,014,000 | +7.9% | 633,663 | -10.3% | 0.08% | 0.0% |
Q4 2020 | $224,235,000 | +32.4% | 706,144 | +3.3% | 0.08% | +15.9% |
Q3 2020 | $169,390,000 | -10.5% | 683,772 | -4.6% | 0.07% | -14.8% |
Q2 2020 | $189,221,000 | +52.7% | 716,553 | +9.6% | 0.08% | +24.6% |
Q1 2020 | $123,957,000 | -21.8% | 653,714 | -9.4% | 0.06% | -1.5% |
Q4 2019 | $158,459,000 | +13.6% | 721,884 | +1.2% | 0.07% | +4.8% |
Q3 2019 | $139,519,000 | +13.4% | 713,036 | +20.8% | 0.06% | +14.5% |
Q2 2019 | $123,032,000 | +11.8% | 590,108 | +6.4% | 0.06% | +7.8% |
Q1 2019 | $110,082,000 | +55.9% | 554,429 | +13.6% | 0.05% | +45.7% |
Q4 2018 | $70,620,000 | -46.8% | 487,976 | -25.0% | 0.04% | -23.9% |
Q3 2018 | $132,824,000 | +24.0% | 650,749 | -10.1% | 0.05% | -2.1% |
Q2 2018 | $107,127,000 | +55.5% | 724,075 | +58.7% | 0.05% | +51.6% |
Q1 2018 | $68,891,000 | +89.4% | 456,111 | +62.4% | 0.03% | +82.4% |
Q4 2017 | $36,375,000 | +49.3% | 280,780 | +39.4% | 0.02% | +41.7% |
Q3 2017 | $24,358,000 | +0.6% | 201,486 | -2.2% | 0.01% | 0.0% |
Q2 2017 | $24,217,000 | +21.9% | 206,099 | +5.4% | 0.01% | +20.0% |
Q1 2017 | $19,869,000 | +9.9% | 195,470 | +11.1% | 0.01% | 0.0% |
Q4 2016 | $18,087,000 | -1.0% | 175,883 | +5.4% | 0.01% | 0.0% |
Q3 2016 | $18,270,000 | -7.2% | 166,846 | -4.4% | 0.01% | -16.7% |
Q2 2016 | $19,687,000 | +18.2% | 174,565 | -0.9% | 0.01% | +20.0% |
Q1 2016 | $16,652,000 | +5.8% | 176,169 | +0.7% | 0.01% | +11.1% |
Q4 2015 | $15,741,000 | -23.6% | 174,912 | -21.5% | 0.01% | -30.8% |
Q3 2015 | $20,597,000 | -18.4% | 222,774 | -13.1% | 0.01% | -7.1% |
Q2 2015 | $25,246,000 | +2.4% | 256,401 | +4.3% | 0.01% | 0.0% |
Q1 2015 | $24,644,000 | +27.3% | 245,717 | +17.3% | 0.01% | +27.3% |
Q4 2014 | $19,355,000 | – | 209,480 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |